share_log

Earnings Beat: Exelixis, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Earnings Beat: Exelixis, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

盈利超预期:Exelixis公司刚刚超越了分析师预测,分析师们已经在更新他们的模型。
Simply Wall St ·  08/08 09:11

Exelixis, Inc. (NASDAQ:EXEL) just released its second-quarter report and things are looking bullish. Statutory earnings performance was extremely strong, with revenue of US$637m beating expectations by 37% and earnings per share (EPS) of US$0.77, an impressive 151%ahead of expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

伊克力西斯(NASDAQ:EXEL)刚刚发布了第二季度报告,看起来非常看好。法定收益表现非常强劲,营业收入为6,3700万美元,超出预期37%,每股收益(EPS)为0.77美元,比预期高151%令人印象深刻。作为投资者,这是一个重要的时间,因为他们可以查看公司报告中公司的业绩,了解专家对明年的预测,在业务预期方面是否有任何变化。因此,我们收集了最新的盈利预测,以了解明年的财务预计。

big
NasdaqGS:EXEL Earnings and Revenue Growth August 8th 2024
NasdaqGS:EXEL的收益和营业收入增长于2024年8月8日

Taking into account the latest results, Exelixis' 20 analysts currently expect revenues in 2024 to be US$2.05b, approximately in line with the last 12 months. Statutory earnings per share are predicted to jump 28% to US$1.57. In the lead-up to this report, the analysts had been modelling revenues of US$1.88b and earnings per share (EPS) of US$1.13 in 2024. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a massive increase in earnings per share in particular.

考虑到最新的结果,伊克力西斯的20名分析师预计2024年的营业收入将达到20.5亿美元,与过去12个月的水平大致相同。法定每股收益预计将跃升28%至1.57美元。在发布报告之前,分析师们一直在建模2024年的营业收入达到18.8亿美元,每股收益为1.13美元。情感有了相当大的提升,分析师们提高了收益并特别增加了每股收益。

Althoughthe analysts have upgraded their earnings estimates, there was no change to the consensus price target of US$27.09, suggesting that the forecast performance does not have a long term impact on the company's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Exelixis analyst has a price target of US$35.07 per share, while the most pessimistic values it at US$18.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

尽管分析师们升级了其收益预测,但共识价格目标仍为27.09美元,表明预测业绩对公司的估值没有长期影响。考虑到分析师预测的范围,评估离群值观点与平均值有多大差异也是有指导意义的。最乐观的伊克力西斯分析师的价格目标为每股35.07美元,而最悲观的则为每股18.00美元。请注意分析师价格目标范围的广泛差异。这对我们来说意味着潜在业务的情景范围相当广泛。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's pretty clear that there is an expectation that Exelixis' revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 3.7% growth on an annualised basis. This is compared to a historical growth rate of 17% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 18% per year. Factoring in the forecast slowdown in growth, it seems obvious that Exelixis is also expected to grow slower than other industry participants.

另一种解读这些估计值的方式是在更大的背景下,比如如何评估预测与过去表现的关系,以及与行业内其他公司相比,预测是否更看好或更不看好。很明显,人们期望伊克力西斯的营业收入增长将大幅放缓,预计到2024年底,年化基础上将实现3.7%的增长。这与过去五年的17%的历史增长率进行对比。与之相比,在此行业中受到分析师覆盖的其他公司预计将以每年18%的速度增长其营业收入。考虑到预期增长放缓,伊克力西斯的增长速度也被认为比其他行业参与者慢。

The Bottom Line

最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Exelixis' earnings potential next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

对我们来说最重要的结论是共识每股收益的升级,这表明明年人们对伊克力西斯的盈利潜力有明显的改善。他们还升级了明年的收入预测,即使预计增长速度比更广泛的行业慢。共识价格目标没有发生实质性变化,这表明业务的内在价值没有随着最新的估计发生重大变化。

With that in mind, we wouldn't be too quick to come to a conclusion on Exelixis. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Exelixis going out to 2026, and you can see them free on our platform here..

因此,我们不应过早得出对伊克力西斯的结论。长期的收益能力比明年的利润更为重要。在Simply Wall St,我们提供了伊克力西斯外延到2026年的完整分析师估计值,您可以在此免费查看。

You still need to take note of risks, for example - Exelixis has 1 warning sign we think you should be aware of.

您仍然需要注意风险,例如-伊克力西斯有1个警告标志我们认为您应该知道。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发